Drug Trial Radar · NCT06545474
Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Sep 15, 2024
Primary completion
Jul 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- University Hospital TuebingenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- German Center for Mental Health
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this randomized multicentre phase 2 clinical trial is to compare the effects of rTMS and SSRI medication as early treatment of depression. In this two-stage, therapy response-adapted trial, 106 patients suffering from non-treatment resistant major depression (non-TR MD) will be randomized in Stage I to either 4 weeks bilateral theta burst stimulation (TBS) or 4 weeks antidepressant SSRI medication. The allocation to Stage II occurs therapy response-adapted. Patients receive either a maintenance treatment or a switch to the respective other treatment arm. The primary outcome is the comparison of the two study arms with regard to therapy response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks at the end of Stage I.
Conditions
- Major Depressive Disorder
Interventions
bilateral theta burst stimulationDevice
Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.
SSRI treatmentDrug
Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- response rates after Stage ITime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Tuebingen
Tübingen, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.